Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0019209 (
hepatomegaly
)
5,798
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Fenarimol
administered in one single or repeated oral doses of 250 or 125 mg/kg body weight per day, respectively, stimulated rat liver enlargement which was associated with a wave of DNA synthesis on the first day after start of treatment. Subsequently, even though fenarimol treatment was continued, the DNA synthesis was suppressed as soon as a new steady liver DNA level was reached. The early hyperplastic episode was evidently primary responsible for the liver growth that occurred within the first 3 days of administration of compound.
Liver enlargement
achieved maximum growth by 3 or 5 days from first administration of 125 and 250 mg fenarimol/kg body weight per day, respectively. This later stage of
hepatomegaly
was mainly due to cellular hypertrophy involving an increase in RLW accompanied by an increase in liver protein content.
Hepatomegaly
and DNA synthesis appeared to be threshold related.
...
PMID:Some biochemical changes associated with fenarimol-induced liver growth in the rat. 184 42